Piper Jaffray downgrades ACADIA Pharmaceuticals (Nasdaq: ACAD) from Neutral to Sell.

Piper analyst says, "We are downgrading ACADIA to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE